ImpediMed boosts U.S. coverage, opens new markets as new CEO takes helm

Impedimed Limited ( (AU:IPD) ) has provided an announcement.

ImpediMed reported third-quarter FY26 revenue of $3.5 million, annual recurring revenue of $14.1 million and net operating cash outflows of $4.5 million, ending the period with $12.7 million in cash. The company’s SOZO core business secured $5.4 million in total contract value, while installed units in leading U.S. hospitals reached 617, backed by 27 master services agreements with major integrated delivery networks.

Reimbursement for breast cancer-related lymphoedema assessments continued to strengthen, with national U.S. coverage rising to 94.3% and 328 million covered lives, supporting both new customer acquisition and deeper utilisation at existing sites. Commercial activities formally commenced in the heart health and weight management markets, with initial sales recorded, and the appointment of former Hologic executive Erik Anderson as CEO is intended to accelerate U.S. growth, deepen health system engagement and move the business toward cash flow break-even.

The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.

More about Impedimed Limited

ImpediMed Limited is an Australian medical technology company focused on digital health solutions for disease detection and management. Its flagship SOZO platform uses bioimpedance spectroscopy to support breast cancer-related lymphoedema, heart failure and body composition monitoring, targeting major U.S. hospital systems and emerging weight management markets.

Average Trading Volume: 5,666,191

Technical Sentiment Signal: Sell

Current Market Cap: A$30.58M

Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.